Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
GERMANTOWN, Maryland, and HILDEN, Germany, June 6, 2013 /PRNewswire/ --
QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that a U.S. reference laboratory customer of its HPV-related products used for cervical cancer screening has made public on June 6 a new non-exclusive agreement to consolidate the purchase of products used for women’s health diagnostics with a competitor supplier.
QIAGEN has been informed that its HPV-related products will continue to be offered by this customer, and also looks forward to working with this customer to continue the strong growth pace of its sales of other products from its portfolio.
QIAGEN offers the industry-leading test for cervical cancer detection, while the competitor product to be added by this customer to its offering fails to address key physician and patient demands for HPV testing. The digene HC2 Test is the “gold standard” FDA-approved molecular test for HPV screening based on annual sales and testing volumes, with more than 90 million tests delivered worldwide since its market introduction. It is supported by clinical data from more than 300 clinical studies in independent, peer-reviewed publications involving more than one million women as well as being the only test proven to support implementation of new five-year interval U.S. screening guidelines.
QIAGEN sees no need at this time to revise its guidance for 2013, and expects that sales related to this development represent less than 2% of its anticipated total net sales for 2014. QIAGEN further expects that sales related to products used in HPV screening in the U.S. to represent less than 10% of total net sales in 2014.
About QIAGEN
QIAGEN N.V., a Netherlands holding company, is the leading global provider of Sample & Assay Technologies that are used to transform biological materials into valuable molecular information. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue. Assay technologies are then used to make these isolated biomolecules visible and ready for interpretation. QIAGEN markets more than 500 products around the world, selling both consumable kits and automation systems to customers through four customer classes: Molecular Diagnostics (human healthcare), Applied Testing (forensics, veterinary testing and food safety), Pharma (pharmaceutical and biotechnology companies) and Academia (life sciences research). As of March 31, 2013, QIAGEN employed approximately 4,000 people in more than 35 locations worldwide. Further information can be found at http://www.qiagen.com/.
Help employers find you! Check out all the jobs and post your resume.
